SG11201500408VA - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents
Extended-release formulation for reducing the frequency of urination and method of use thereofInfo
- Publication number
- SG11201500408VA SG11201500408VA SG11201500408VA SG11201500408VA SG11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA
- Authority
- SG
- Singapore
- Prior art keywords
- urination
- extended
- frequency
- reducing
- release formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/424,000 US8236857B2 (en) | 2010-07-08 | 2012-03-19 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US13/487,348 US20120244221A1 (en) | 2010-07-08 | 2012-06-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| PCT/US2013/030901 WO2013142197A1 (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500408VA true SG11201500408VA (en) | 2015-03-30 |
Family
ID=49223209
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500408VA SG11201500408VA (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| SG11201500409SA SG11201500409SA (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500409SA SG11201500409SA (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2827852A4 (xx) |
| JP (5) | JP2015510928A (xx) |
| KR (4) | KR20140134333A (xx) |
| CN (4) | CN107157991A (xx) |
| AU (4) | AU2013235518B2 (xx) |
| BR (2) | BR112014020271A8 (xx) |
| CA (2) | CA2866853A1 (xx) |
| HK (3) | HK1204553A1 (xx) |
| MX (3) | MX2014011128A (xx) |
| MY (2) | MY174090A (xx) |
| NZ (6) | NZ712594A (xx) |
| RU (3) | RU2669565C2 (xx) |
| SG (2) | SG11201500408VA (xx) |
| WO (2) | WO2013142197A1 (xx) |
| ZA (2) | ZA201405862B (xx) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| MX2016001030A (es) | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
| KR20170010440A (ko) * | 2014-06-06 | 2017-01-31 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도를 감소시키기 위한 약학적 제형 및 이의 사용방법 |
| KR101809908B1 (ko) | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | 5-알파환원효소억제제를 포함하는 조성물 |
| US10286033B2 (en) * | 2014-11-20 | 2019-05-14 | Serenity Pharmaceuticals, Llc | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
| AU2016331879A1 (en) * | 2015-09-30 | 2018-05-17 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| CN108391420A (zh) * | 2015-09-30 | 2018-08-10 | 韦尔斯利医药有限公司 | 用于减少排尿频率的组合物及其制备方法和应用 |
| CN105238124B (zh) * | 2015-11-16 | 2018-02-09 | 太仓东能环保设备有限公司 | 一种抗菌腻子粉 |
| JP6294924B2 (ja) | 2016-09-05 | 2018-03-14 | 株式会社Ｓｕｂａｒｕ | 車両の走行制御装置 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999040942A1 (fr) * | 1998-02-10 | 1999-08-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations a liberation controlee |
| US20020102309A1 (en) * | 1999-09-14 | 2002-08-01 | Jane C. I. Hirsh | Controlled release formulation for administration of an anti-inflammatory naphthalene derivative |
| DE10116978A1 (de) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| AU2003211078A1 (en) * | 2002-02-19 | 2003-09-09 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| RU2004135563A (ru) * | 2002-06-07 | 2005-06-10 | Яманоути Фармасьютикал Ко.,Лтд. (Jp) | Лекарственное средство для лечения повышенной активности мочевого пузыря |
| US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
| KR100742001B1 (ko) * | 2003-03-21 | 2007-07-23 | 다이노젠 파마세우티컬스, 인코포레이티드 | 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법 |
| KR101113005B1 (ko) * | 2003-03-21 | 2012-02-24 | 맥네일-피피씨, 인코포레이티드 | 비-스테로이드계 항염증성 약물 투여법 |
| EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
| EP2248524A3 (en) * | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| US20070021357A1 (en) * | 2005-06-17 | 2007-01-25 | Dynamis Therapeutics, Inc. | Treatment of inflammatory conditions |
| US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| JP5312027B2 (ja) * | 2005-09-02 | 2013-10-09 | セラヴィダ、インク | 病気の治療法 |
| WO2010138441A1 (en) * | 2009-05-28 | 2010-12-02 | Aptapharma, Inc. | Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen |
| GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| US20120244221A1 (en) * | 2010-07-08 | 2012-09-27 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
-
2013
- 2013-03-13 MY MYPI2014702434A patent/MY174090A/en unknown
- 2013-03-13 KR KR1020147029163A patent/KR20140134333A/ko not_active Application Discontinuation
- 2013-03-13 WO PCT/US2013/030901 patent/WO2013142197A1/en active Application Filing
- 2013-03-13 EP EP13763764.1A patent/EP2827852A4/en not_active Withdrawn
- 2013-03-13 CN CN201710373440.5A patent/CN107157991A/zh active Pending
- 2013-03-13 RU RU2014142025A patent/RU2669565C2/ru not_active IP Right Cessation
- 2013-03-13 SG SG11201500408VA patent/SG11201500408VA/en unknown
- 2013-03-13 NZ NZ712594A patent/NZ712594A/en not_active IP Right Cessation
- 2013-03-13 JP JP2015501754A patent/JP2015510928A/ja active Pending
- 2013-03-13 NZ NZ714288A patent/NZ714288A/en not_active IP Right Cessation
- 2013-03-13 BR BR112014020271A patent/BR112014020271A8/pt not_active Application Discontinuation
- 2013-03-13 AU AU2013235518A patent/AU2013235518B2/en not_active Ceased
- 2013-03-13 CA CA2866853A patent/CA2866853A1/en not_active Abandoned
- 2013-03-13 MX MX2014011128A patent/MX2014011128A/es unknown
- 2013-03-13 NZ NZ718163A patent/NZ718163A/en not_active IP Right Cessation
- 2013-03-13 NZ NZ630471A patent/NZ630471A/en not_active IP Right Cessation
- 2013-03-13 CN CN201380015062.3A patent/CN104302284A/zh active Pending
- 2013-03-14 CA CA2866755A patent/CA2866755A1/en not_active Abandoned
- 2013-03-14 CN CN201380015025.2A patent/CN104321056A/zh active Pending
- 2013-03-14 RU RU2016133305A patent/RU2016133305A/ru not_active Application Discontinuation
- 2013-03-14 BR BR112014020113A patent/BR112014020113A8/pt not_active Application Discontinuation
- 2013-03-14 SG SG11201500409SA patent/SG11201500409SA/en unknown
- 2013-03-14 KR KR1020187038194A patent/KR20190003840A/ko not_active Application Discontinuation
- 2013-03-14 EP EP13763665.0A patent/EP2827851A4/en not_active Withdrawn
- 2013-03-14 KR KR1020177002422A patent/KR20170015537A/ko active Application Filing
- 2013-03-14 NZ NZ714662A patent/NZ714662A/en not_active IP Right Cessation
- 2013-03-14 RU RU2014142066/15A patent/RU2599017C2/ru not_active IP Right Cessation
- 2013-03-14 CN CN201711086139.2A patent/CN107789626A/zh active Pending
- 2013-03-14 JP JP2015501785A patent/JP2015510936A/ja active Pending
- 2013-03-14 KR KR20147024604A patent/KR20140134284A/ko active Search and Examination
- 2013-03-14 MX MX2014011129A patent/MX2014011129A/es unknown
- 2013-03-14 AU AU2013235507A patent/AU2013235507B2/en not_active Ceased
- 2013-03-14 NZ NZ628079A patent/NZ628079A/en not_active IP Right Cessation
- 2013-03-14 MY MYPI2014702174A patent/MY175764A/en unknown
- 2013-03-14 WO PCT/US2013/031617 patent/WO2013142274A1/en active Application Filing
-
2014
- 2014-08-11 ZA ZA2014/05862A patent/ZA201405862B/en unknown
- 2014-08-21 ZA ZA2014/06146A patent/ZA201406146B/en unknown
- 2014-09-17 MX MX2019008817A patent/MX2019008817A/es unknown
-
2015
- 2015-05-27 HK HK15105034.0A patent/HK1204553A1/xx unknown
- 2015-05-27 HK HK18110965.0A patent/HK1251469A1/zh unknown
-
2016
- 2016-05-04 JP JP2016092868A patent/JP2016172752A/ja active Pending
-
2017
- 2017-05-11 AU AU2017203139A patent/AU2017203139B2/en not_active Ceased
- 2017-05-15 AU AU2017203246A patent/AU2017203246B2/en not_active Ceased
- 2017-09-20 JP JP2017179685A patent/JP2018024693A/ja active Pending
-
2018
- 2018-03-10 HK HK18103371.3A patent/HK1243921A1/zh unknown
- 2018-05-15 JP JP2018093416A patent/JP2018138602A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274404A (en) | Body expandable device and method for use | |
| IL261768B (en) | Devices and methods for tissue treatment | |
| HK1243921A1 (zh) | 用於緩解尿頻的延長釋放製劑及其使用方法 | |
| IL232715A0 (en) | The delayed-release composition for reducing the frequency of urination and a method for using it | |
| HK1200690A1 (en) | Expandable body device and method of use | |
| ZA201403762B (en) | Delayed-release formulation for reducing the frequency of urination and method of use thereof | |
| EP2709562A4 (en) | FABRIC BACKUP DEVICES AND USE METHOD THEREFOR | |
| RS59200B1 (sr) | Derivati c4-monometil triterpenoida i postupci za njihovu upotrebu | |
| EP2613735A4 (en) | DEVICES AND METHODS FOR THE TREATMENT OF VASCULAR ABNORMALITIES | |
| EP2825242A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS | |
| EP2790709A4 (en) | HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF | |
| EP2938289A4 (en) | DEVICES AND METHODS FOR TREATING VASCULAR DEFECTS | |
| IL261232A (en) | A pharmaceutical formulation for reducing urinary frequency and a method for its use | |
| HK1249438A1 (zh) | 用於緩解尿頻的緩釋製劑及其使用方法 | |
| HK1203395A1 (en) | Implantable devices and methods for the evaluation of active agent | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| HK1248549A1 (zh) | 用於緩解尿頻的延長釋放製劑及其使用方法 | |
| HK1203159A1 (en) | Prophylactic agent and or therapeutic agent for stress urinary incontinence | |
| AP3759A (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same |